From 1992 to 1997 , 13,388 women with estimated 5-year breast cancer risk greater than 1.66 % or a history of lobular carcinoma in situ ( 87 % younger than age 65 ; 67 % postmenopausal ) were randomly assigned to tamoxifen versus placebo .